Skip to main content

Bobo Donald E Jr's Form 4 filing

Edwards Lifesciences Corp (EW) · filed Aug 9, 2022

Accession no.
0001225208-22-009404
Filed
Aug 9, 2022
Trade date
Aug 9, 2022
Filing delay
Same day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $706.2K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bobo Donald E JrCIK 0001196661Officer (CVP,Strategy/Corp Development)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 9, 2022Common StockMOption exerciseAcquired+6,725$35.20+$236,72069,285.78Direct
Aug 9, 2022Common StockSSaleDisposed−6,725$105.01−$706,192.2562,560.78Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 9, 2022Common StockMOption exerciseDisposed−6,725$0.00$053,800Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

Read the full filing on SEC EDGAR (opens in a new tab)